Novel immune-based therapies for psoriasis

British Journal of Dermatology

Volumn 146, Issue 4, 2002, Pages 546-551

  Kirby, B ^a   Griffiths, Christopher E M ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

Cytokines; Immune therapy; Innate immunity; Psoriasis; T cells

Indexed keywords

ALEFACEPT; ANTIPSORIASIS AGENT; CD11A MONOCLONAL ANTIBODY; CELL ADHESION MOLECULE; CYCLOSPORIN; CYTOKINE ANTIBODY; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; E SELECTIN ANTIBODY; EFLALIZUMAB; ETANERCEPT; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; INTERLEUKIN 1; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 18 MONOCLONAL ANTIBODY; INTERLEUKIN 2 RECEPTOR ANTIBODY; INTERLEUKIN 4; METHOTREXATE; MONOCLONAL ANTIBODY CD 2; OKT 4; PLACEBO; PROTEIN ANTIBODY; SIPLIZUMAB; T LYMPHOCYTE RECEPTOR; TACROLIMUS; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANTIGEN PRESENTING CELL; AUTOIMMUNE DISEASE; CLINICAL TRIAL; CROHN DISEASE; DISEASE SEVERITY; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG TOLERABILITY; FEVER; HEADACHE; HUMAN; IMMUNE SYSTEM; IMMUNITY; IMMUNOTHERAPY; LYMPHOCYTE COUNT; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PSORIASIS; REVIEW; RHEUMATOID ARTHRITIS; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; TREATMENT OUTCOME;

CYTOKINES; HUMANS; IMMUNOTHERAPY; PSORIASIS; T-LYMPHOCYTE SUBSETS;

EID: 0036239694     PISSN: 00070963     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2133.2002.04760.x     Document Type: Review

References (39)

1. Psoriasis: A T-cell-mediated autoimmune disease induced by streptococcal super-antigens?
2. Long-term cyclosporin for psoriasis
3. Response of psoriasis to a lymphocyte-selective toxin (DAB389IL-2) suggests a primary immune, but not keratinocyte, pathogenic basis
4. A multicenter dose-escalation trial with denileukin diftitox (ONTAK, DAB389IL-2) in patients with severe psoriasis
5. Clearing of psoriasis by a novel immunosuppressive macrolide
6. Successful in vivo blockade of CD25 (high-affinity interleukin 2 receptor) on T cells by administration of humanized anti-Tac antibody to patients with psoriasis
7. Successful treatment of severe psoriasis with basiliximab, an interleukin-2 receptor monoclonal antibody
8. Treatment of severe psoriasis with anti-CD25 monoclonal antibodies
9. Successful treatment of severe generalized pustular psoriasis with basiliximab (interleukin-2 receptor blocker)
10. Anti-CD4 monoclonal antibody treatment of moderate to severe psoriasis vulgaris: Results of a pilot, multicenter, multiple-dose, placebo-controlled study
11. Anti-CD4 monoclonal antibody therapy in severe psoriasis
12. Subcutaneous injection of Medi-507 (siplizumab), an anti-T cell monoclonal antibody for the treatment of psoriasis: Phase I results
13. Phase I results of intravenous MEDI-507 (siplizumab), an anti-T cell monoclonal antibody, for the treatment of psoriasis
14. Treatment of chronic plaque psoriasis by selective targeting of memory effector T lymphocytes
15. CTLA4Ig-mediated blockade of T-cell costimulation in patients with psoriasis vulgaris
16. Blockade of T lymphocyte costimulation with cytotoxic T lymphocyte-associated antigen 4-immunoglobulin (CTLA4Ig) reverses the cellular pathology of psoriatic plaques, including the activation of keratinocytes, dendritic cells, and endothelial cells
17. CTLA4-Ig: A novel immunosuppressive agent
18. The treatment of moderate to severe psoriasis with a new anti-CD11a monoclonal antibody
19. The ICAM-3/LFA-1 interaction is critical for epidermal Langerhans cell alloantigen presentation to CD4+ T cells
20. Cutaneous leukocyte trafficking and psoriasis
21. Anti-E-selectin is ineffective in the treatment of psoriasis: A randomized trial
22. On the role of the innate immunity in autoimmune disease
23. The role of natural killer cells in psoriasis
24. The majority of epidermal T cells in psoriasis vulgaris lesions can produce type 1 cytokines, interferon-gamma, interleukin-2, and tumor necrosis factor-alpha, defining TC1 (cytotoxic T lymphocyte) and TH1 effector populations: A type 1 differentiation bias is also measured in circulating blood T cells in psoriatic patients
25. Expression of interleukin-12 is increased in psoriatic skin
26. Neutrophil chemoattractant and IL-1-like activity in samples from psoriatic skin lesions. Further characterization
27. Elevated tumour necrosis factor-alpha (TNF-alpha) biological activity in psoriatic skin lesions
28. Psoriasis: The future
29. Effects of systemic interleukin-10 therapy on psoriatic skin lesions: Histologic, immunohistologic, and molecular biology findings
30. Treatment of psoriasis with interleukin-10
31. Interleukin-4 induced immune deviation as therapy for psoriasis
32. Clinical trials of a fully human anti-IL-8 antibody for the treatment of psoriasis
33. Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: A randomised trial
34. Etanercept in the treatment of psoriatic arthritis and psoriasis: A randomised trial
35. Treatment of psoriatic arthritis with antitumour necrosis factor-alpha antibody clears skin lesions of psoriasis resistant to treatment with methotrexate
36. Successful treatment of severe recalcitrant psoriasis with combination infliximab and methotrexate
37. Etanercept for severe psoriasis and psoriatic arthritis: Observations on combination therapy
38. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent
39. Crohn's disease: Genetic susceptibility, bacteria, and innate immunity